Exagen (XGN) EBT (2018 - 2026)

Exagen has reported EBT for 9 years, with the latest figure at -$3.9 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 4.77% year-over-year to -$3.9 million; the trailing twelve-month figure through Mar 2026 stood at -$20.1 million (down 29.58% YoY), and the FY2025 full-year result was -$19.9 million, down 31.76% from the prior year.
• EBT for Q1 2026 stood at -$3.9 million, up from -$4.7 million in the prior quarter.
• The five-year high for EBT was -$3.0 million in Q2 2024, with the low at -$15.1 million in Q4 2022.
• Historically, EBT has averaged -$6.5 million across 5 years, with a median of -$5.0 million in 2024.
• Annual changes were most pronounced in 2022 — EBT sank 128.86% — and 2023, when it surged 65.83%.
• Exagen's EBT stood at -$15.1 million in 2022, then surged by 63.35% to -$5.5 million in 2023, then jumped by 32.33% to -$3.7 million in 2024, then fell by 24.3% to -$4.7 million in 2025, then gained by 15.64% to -$3.9 million in 2026.
• The last three EBT figures came in at -$3.9 million (Q1 2026), -$4.7 million (Q4 2025), and -$7.1 million (Q3 2025), per Business Quant data.